DouglasMichaelSprouleMD
Child Neurology • New York, NYAssistant Professor of Neurology, Columbia University Medical Center
Dr. Sproule is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
180 Fort Washington Ave Fl 5
Harkness Pavilion, Columbia-Presbyterian Medical Center
New York, NY 10032Phone+1 212-342-3679- Is this information wrong?
Education & Training
New York Presbyterian Hospital (Cornell Campus)Fellowship, Child Neurology, 2005 - 2008- New York Presbyterian Hospital (Columbia Campus)Residency, Child Neurology, 2003 - 2006
Tower Health/St. Christopher's Hospital for ChildrenResidency, Pediatrics, 2003 - 2005
Columbia University Vagelos College of Physicians and SurgeonsClass of 2003
Certifications & Licensure
NY State Medical License 2005 - 2025
MA State Medical License 2013 - 2014- American Board of Psychiatry and Neurology Neurology with Special Qualification in Child Neurology
- American Board of Psychiatry and Neurology Neuromuscular Medicine
Clinical Trials
- Clinical Study of Spinal Muscular Atrophy Start of enrollment: 2005 May 01
- Giant Axonal Neuropathy Natural History Study Start of enrollment: 2011 Dec 01
Publications & Presentations
PubMed
- 45 citationsBiodistribution of onasemnogene abeparvovec DNA, mRNA and SMN protein in human tissue.Gretchen Thomsen, Arthur H.M. Burghes, Caroline Hsieh, Janet Do, Binh T. T. Chu, Stephanie Perry, Basam Barkho, Petra Kaufmann, Douglas M. Sproule, Douglas E. Feltner,...> ;Nature Medicine. 2021 Oct 1
- 174 citationsOnasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, ...John W. Day, Richard S. Finkel, Claudia A. Chiriboga, Anne M. Connolly, Thomas O. Crawford, Basil T. Darras, Susan T. Iannaccone, Nancy L. Kuntz, Loren D M Pena, Perry...> ;The Lancet. Neurology. 2021 Apr 1
- 25 citationsAn updated cost-utility model for onasemnogene abeparvovec (Zolgensma®) in spinal muscular atrophy type 1 patients and comparison with evaluation by the Institute for ...Rebecca Dean, Ivar Jensen, Phil Cyr, Beckley Miller, Benit Maru, Douglas M. Sproule, Douglas E. Feltner, Thomas Wiesner, Daniel C. Malone, Matthias Bischof, Walter Tor...> ;Journal of Market Access & Health Policy. 2021 Feb 28
- Join now to see all
Press Mentions
- BridgeBio Pharma to Present Preliminary Findings on Its Novel Bioassay Measuring Glycosylated Alpha-Dystroglycan (⍺DG) in Patients with Limb-Girdle Muscular Dystrophy Type 2I (LGMD2I)March 17th, 2023
- BridgeBio Pharma (BBIO) Reports 12-Month Results from Phase 2 Study of BBP-418October 14th, 2022
Dosing Begins in Phase 2 Trial Testing Oral Therapy BBP-418 for LGMD2iMarch 2nd, 2021- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
